

November 09, 2022

|  |   |
|--|---|
| To,<br>BSE Limited<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street, Mumbai- 400 001<br><b>Scrip Code: 532967</b> | To,<br>National Stock Exchange of India Limited<br>Exchange Plaza, Bandra Kurla Complex,<br>Bandra (E), Mumbai - 400 051<br><b>Scrip ID - KIRIINDUS</b> |
|--|---|

Dear Sir/Madam,

**Sub: Submission of Earnings Presentation for Q2-FY23 as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.**

In compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and our letter dated November 08, 2022 regarding intimation of Conference Call scheduled to be held on Thursday, November 10, 2022 at 11.00 a.m. (IST), please find attached herewith the Q2-FY23 Earnings Presentation.

The Q2-FY23 Earnings Presentation is also available on website of the Company at [www.kiriindustries.com](http://www.kiriindustries.com).

You are kindly requested to take note of the same.

Thanking You,

Yours faithfully,

**For Kiri Industries limited**

**Suresh Gondalia**  
**Company Secretary**  
Encl: As stated

**DYES**

Plot No 299/1/A & B, Phase-II, Nr. Water Tank, GIDC, Vatva,  
Ahmedabad - 382 445, Gujarat, India  
**Phone:** +91-79-25894477  
**Fax:** +91-79-25834960  
**Email:** [engage@kiriindustries.com](mailto:engage@kiriindustries.com) **Web:** [www.kiriindustries.com](http://www.kiriindustries.com)

**INTERMEDIATES**

Plot No: 396/399/403/404 EPC Canal Road, Village: Dudhwada,  
Ta: Padra, Dist: Vadodara - 391450 Gujarat, India.  
**Phone:** +91-2662-273444  
**Fax:** +91-2662-273444  
**Email:** [intermediates@kiriindustries.com](mailto:intermediates@kiriindustries.com) **Web:** [www.kiriindustries.com](http://www.kiriindustries.com)


**CHEMICALS**

Plot No : 552, 566, 567, 569-71 Village: Dudhwada, Tal.: Padra,  
Dist. : Vadodara-391450 Gujarat, India.  
**Phone:** +91-2662-273724, 25  
**Fax:** +91-2662-273726  
**Email:** [intermediates@kiriindustries.com](mailto:intermediates@kiriindustries.com) **Web:** [www.kiriindustries.com](http://www.kiriindustries.com)



Kiri Industries Limited

*Future Full of Colours.....*



CHEMISTRY OF


**COLOURS**

Q2/H1-FY23 | EARNINGS PRESENTATION


# Company Overview



Consolidated Revenue Break-up (INR Mn)



Standalone Revenue Breakup (FY22)



- Established in 1998, Kiri Industries Limited (KIL), is based out of Gujarat and has emerged as one of the largest manufacturers and exporters of a wide range of Dyes, Dyes Intermediates and Basic Chemicals from India with 'Zero Effluent'.
- KIL is an accredited and certified Key Business Partner with world's top Dyestuff majors across Asia-Pacific, the EU and America.
- It provides products and services across the whole value chain in numerous industrial sectors (apparel, hosiery, automotive, carpets, leather, paper, home upholstery, industrial fabrics, etc.)
- In the 22 years of the Company's corporate journey, KIL has been focusing on providing products of high quality standards, executing collaborations and strategic acquisitions, implementing environmentally aligned R&D, finding innovative solution centric and all-encompassing customer care
- All initiatives taken by KIL has enabled it to set its footprints in over 50 countries across 7 continents.
- The Company has sizeable manufacturing facility of Dyes Intermediates and Basic chemicals at Padra (Baroda, Gujarat) and to strengthen its competitive edge in dyes vertical, KIL formed a joint venture with Longsheng (China) and set up a manufacturing facility for dyes.


# About DyStar




**KIL acquired DyStar  
in 2010, along with  
Zhenjiang Longsheng  
holding 37.57%  
presently**

- The DyStar Group is a leading dyestuff and chemical manufacturer and solution provider, offering a broad portfolio of colorants, specialty chemicals, and services to customers across the globe.
- With a heritage of more than a century in product development and innovation for the textile industry, DyStar also caters to multiple sectors including paints, coatings, paper and packaging industries. Its expansion into food and beverages and personal care sectors reinforces the company's position as a specialty chemical manufacturer.
- DyStar's global presence offers customers reliable access to experts from offices, competence centres, agencies and production plants spanning over 50 countries.
- DyStar has 16 manufacturing plants with a combined production capacity of 176,000 TPA. It is a market leader in global dyes market with a market share of over ~21%.
- It has expertise in dyes, dyes solutions, leather solutions, performance chemicals, and custom manufacturing of special dyes/pigments.

Total Revenue (USD Mn)



Profit after Tax (USD Mn)



\* Includes disputed provisions / write off in CY18 and CY19 of USD 113.02 Mn and USD 26.56 Mn respectively

# History

DyStar was founded in 1995 as a joint venture between Hoechst AG and Bayer Textile Dyes. In 2000, the textile dyes business from BASF was integrated. In 2010, DyStar Group was acquired by Kiri Industries Limited (KIL).

1995

**FOUNDATION JOINT VENTURE OF:**  
 Bayer AG and Hoechst AG (Textile dyes, Ind. Mitsubishi)



2002

**ACQUISITION:**  
 Color Solutions International



2007

**ACQUISITION:**  
 Texanlab




2012

**FOUNDATION:**  
 Sustainable Textile Solutions



2016

**ACQUISITION:**  
 Emerald Performance Materials Specialities Group



**JOINT VENTURE OF:**  
 Bayer AG, Hoechst AG, BASF AG (Textile dyes, Ind. ICI/Zeneca dyes and Mitsui)

2000

**LAUNCH:**  
 E-confidence program

**ACQUISITION:**  
 Yorkshire Americas, Rotta Group and Boehme Group

2004-06

**ACQUISITION BY KIL**

2010

**ACQUISITION:**  
 Lenmar Chemicals (Business and Assets)

2013

# Financial Highlights

## Q2-FY23 Financial Highlights (Consolidated)

Operational Revenue  
INR 2,422 Mn

EBITDA\*  
INR (71) Mn

EBITDA Margin\*  
NA

Net Profit\*  
INR (262) Mn

PAT Margin\*  
NA

Diluted EPS  
INR **11.70**

## H1-FY23 Financial Highlights (Consolidated)

Operational Revenue  
INR 5,188 Mn

EBITDA\*  
INR (156) Mn

EBITDA Margin\*  
NA

Net Profit\*  
INR (526) Mn

PAT Margin\*  
NA

Diluted EPS  
INR 22.03

## Q2-FY23 Financial Highlights (Standalone)

Operational Revenue  
INR 1,407 Mn

EBITDA  
INR (319) Mn

EBITDA Margin  
NA

Net Profit  
INR (439) Mn

PAT Margin  
NA

Diluted EPS  
INR (8.47)

## H1-FY23 Financial Highlights (Standalone)

Operational Revenue  
INR 3,121 Mn

EBITDA  
INR (638) Mn

EBITDA Margin  
NA

Net Profit  
INR (718) Mn

PAT Margin  
NA

Diluted EPS  
INR (13.84)

# Q2-FY23 Operational Highlights

## Consolidated:

Global business environment has become susceptible to Russia-Ukraine War for more than 34 weeks. Additionally, China recently announced New Covid-Zero measures wherein 28 Cities are implementing varying degrees of lockdown, which made global Dyes and Dyes Intermediates products more volatile, impacting growth of the industry.

During Q2-FY23, the industry experienced very sluggish demand resulting in lower capacity utilisations and not allowing the company to pass on the increase in cost to its customers.

The prices of raw material, gas & fuel which had increased during preceding two quarters have not reduced during the current quarter, which impacted margins of all dyes and dyes intermediates units of the industry.

## Standalone:

The major reason for negative EBIDTA, was sluggish demand and lower capacity utilization with conversion cost not getting fully absorbed and most importantly not being able to pass on the cost increases to customers. High legal costs have also impacted margins.

The raw material prices remained stagnant in Q2-FY23, after being volatile in the preceding two to three quarters. Currently operational margins are in negative zone, which should improve once global markets stabilize and demand starts picking up.

The sluggish demand and volatile raw material prices increased the payment cycle and reduced inventory churning.

# Update on DyStar court case in Singapore

---

The Supreme Court of Singapore (Court of Appeal) has given judgement dated 6 July, 2022 in SIC4, Kiri has prevailed on the issues in the Supreme Court with regards to 19% Discount for lack of marketability (DLOM) and the quantum of the licence fee for wrongful exploitation of Patent. The Supreme Court had remanded the matter back to Singapore International Commercial Court (SICC) to give an effect to the decisions and to determine the quantum of notional licence fee based on available evidences submitted by both parties and reversal of DLOM. As per direction of the SICC, related submission from parties had been completed, and final valuation order is awaited.

---

In another appeal against cost order of SICC date 8 December, 2021, hearing at Supreme Court of Singapore had been completed on 16 September, 2022 and order from Supreme Court of Singapore is reserved and awaited.

---

In SIC7, Kiri and DyStar had filed appeal against SICC order with regards to preferred supplier status to Kiri. SICC had rejected Kiri's claim related to be treated as preferred supplier against DyStar vide its order dated 24 September, 2021. The hearing of Appeal at Supreme Court of Singapore had been Completed on 22 September, 2022 and order is reserved and awaited.





# Q2/H1-FY23 FINANCIAL HIGHLIGHTS

# Q2-FY23 Standalone Income Statement

| PARTICULARS (INR Mn)        | Q2-FY23 | Q2-FY22 | Y-o-Y   | Q1-FY23 | Q-o-Q   |
|-----------------------------|---------|---------|---------|---------|---------|
| Revenue from Operations     | 1,407   | 2,633   | (46.6)% | 1,714   | (17.9)% |
| Total Expenses              | 1,726   | 2,633   | (34.4)% | 2,032   | (15.1)% |
| EBITDA                      | (319)   | 0       | NA      | (318)   | NA      |
| <i>EBITDA Margins (%)</i>   | NA      | NA      | NA      | NA      | NA      |
| Other Income                | 1       | 4       | (75.0)% | 151     | (99.3)% |
| Depreciation                | 111     | 109     | 1.8%    | 109     | 1.8%    |
| Finance Cost                | 12      | 11      | 9.1%    | 13      | (7.7)%  |
| PBT                         | (441)   | (116)   | NA      | (289)   | NA      |
| Tax                         | (2)     | (42)    | NA      | (10)    | NA      |
| Profit After Tax            | (439)   | (74)    | NA      | (279)   | NA      |
| <i>PAT Margins (%)</i>      | NA      | NA      | NA      | NA      | NA      |
| Other Comprehensive Income  | -       | -       | NA      | -       | NA      |
| Total Comprehensive Income  | (439)   | (74)    | NA      | (279)   | NA      |
| Diluted EPS (INR per share) | (8.47)  | (1.43)  | NA      | (5.37)  | NA      |

# H1-FY23 Standalone Income Statement

| PARTICULARS (INR Mn)       | H1-FY23 | H1-FY22 | Y-o-Y   |
|----------------------------|---------|---------|---------|
| Revenue from Operations    | 3,121   | 4,628   | (32.6)% |
| Total Expenses             | 3,759   | 4,665   | (19.4)% |
| EBITDA                     | (638)   | (37)    | NA      |
| EBITDA Margin(%)           | NA      | NA      | NA      |
| Other Income               | 153     | 8       | NA      |
| Depreciation               | 221     | 218     | 1.4%    |
| Finance Cost               | 24      | 20      | 20.0%   |
| PBT                        | (730)   | (267)   | NA      |
| Tax                        | (12)    | (97)    | NA      |
| Profit After Tax           | (718)   | (170)   | NA      |
| PAT Margin(%)              | NA      | NA      | NA      |
| Other Comprehensive Income | -       | -       | NA      |
| Total Comprehensive Income | (718)   | (170)   | NA      |
| Diluted EPS (INR)          | (13.84) | (3.29)  | NA      |

# Q2-FY23 Consolidated Income Statement

| PARTICULARS (INR Mn)              | Q2-FY23      | Q2-FY22      | Y-o-Y          | Q1-FY23      | Q-o-Q        |
|-----------------------------------|--------------|--------------|----------------|--------------|--------------|
| Revenue from Operations           | 2,422        | 3,579        | (32.3)%        | 2,767        | (12.5)%      |
| Total Expenses                    | 2,493        | 3,300        | (24.5)%        | 2,852        | (12.6)%      |
| <b>EBITDA</b>                     | <b>(71)</b>  | <b>279</b>   | <b>NA</b>      | <b>(85)</b>  | <b>NA</b>    |
| <i>EBITDA Margins (%)</i>         | <i>NA</i>    | <i>7.80%</i> | <i>NA</i>      | <i>NA</i>    | <i>NA</i>    |
| Other Income                      | 2            | 5            | (60.0)%        | 1            | NA           |
| Depreciation                      | 123          | 128          | (3.9)%         | 122          | 0.8%         |
| Finance Cost                      | 13           | 11           | 18.2%          | 13           | NA           |
| <b>PBT</b>                        | <b>(205)</b> | <b>145</b>   | <b>NA</b>      | <b>(219)</b> | <b>NA</b>    |
| Tax                               | 57           | 21           | NA             | 45           | 26.7%        |
| <b>Profit After Tax</b>           | <b>(262)</b> | <b>124</b>   | <b>NA</b>      | <b>(264)</b> | <b>NA</b>    |
| <i>PAT Margins (%)</i>            | <i>NA</i>    | <i>3.46%</i> | <i>NA</i>      | <i>NA</i>    | <i>NA</i>    |
| Share of Profit of Associates     | 868          | 888          | (2.3)%         | 799          | 8.6%         |
| Other Comprehensive Income        | -            | -            | NA             | -            | NA           |
| <b>Total Comprehensive Income</b> | <b>607</b>   | <b>1,012</b> | <b>(40.0)%</b> | <b>535</b>   | <b>13.5%</b> |
| Diluted EPS (INR per share)       | 11.70        | 19.52        | (40.1)%        | 10.32        | 13.4%        |

# H1-FY23 Consolidated Income Statement

| PARTICULARS (INR Mn)              | H1-FY23      | H1-FY22      | Y-o-Y          |
|-----------------------------------|--------------|--------------|----------------|
| Revenue from Operations           | 5,188        | 6,507        | (20.3)%        |
| Total Expenses                    | 5,344        | 6,027        | (11.3)%        |
| <b>EBITDA</b>                     | <b>(156)</b> | <b>480</b>   | <b>NA</b>      |
| <i>EBITDA Margins (%)</i>         | <i>NA</i>    | <i>7.38%</i> | <i>NA</i>      |
| Other Income                      | 3            | 9            | (66.7)%        |
| Depreciation                      | 245          | 255          | (3.9)%         |
| Finance Cost                      | 26           | 21           | (23.8)%        |
| <b>PBT</b>                        | <b>(424)</b> | <b>213</b>   | <b>NA</b>      |
| Tax                               | 102          | 21           | NA             |
| <b>Profit After Tax</b>           | <b>(526)</b> | <b>192</b>   | <b>NA</b>      |
| <i>PAT Margins (%)</i>            | <i>NA</i>    | <i>2.95%</i> | <i>NA</i>      |
| Share of Profit of Associates     | 1,668        | 1,725        | (3.3)%         |
| Other Comprehensive Income        | -            | -            | NA             |
| <b>Total Comprehensive Income</b> | <b>1,142</b> | <b>1,917</b> | <b>(40.4)%</b> |
| Diluted EPS (INR)**               | 22.03        | 36.99        | (40.4)%        |

\*\*After considering share of profit of associate

# HISTORICAL FINANCIALS

# Historical Standalone Income Statement

| PARTICULARS (INR Mn)        | FY20  | FY21   | FY22   | H1-FY23 |
|-----------------------------|-------|--------|--------|---------|
| Revenue from Operations     | 9,690 | 6,892  | 11,368 | 3,121   |
| Total Expenses              | 8,729 | 6,901  | 11,054 | 3,759   |
| EBITDA                      | 961   | (9)    | 314    | (638)   |
| <i>EBITDA Margins (%)</i>   | 9.92% | NA     | 2.76%  | NA      |
| Other Income                | 41    | 20     | 18     | 153     |
| Depreciation                | 366   | 390    | 436    | 221     |
| Finance Cost                | 45    | 38     | 46     | 24      |
| PBT                         | 591   | (417)  | (150)  | (730)   |
| Tax                         | 89    | (52)   | (57)   | (12)    |
| Profit After Tax            | 502   | (365)  | (93)   | (718)   |
| <i>PAT Margins (%)</i>      | 5.18% | NA     | NA     | NA      |
| Other Comprehensive Income  | (4)   | (2)    | (3)    | -       |
| Total Comprehensive Income  | 498   | (367)  | (96)   | (718)   |
| Diluted EPS (INR per share) | 9.61  | (7.08) | (1.85) | (13.84) |

# Standalone Balance Sheet

| PARTICULARS (INR Mn)                           | FY21          | FY22          | H1-FY23      | PARTICULARS (INR Mn)                  | FY21          | FY22          | H1-FY23      |
|--|---------------|---------------|--------------|---------------------------------------|---------------|---------------|--------------|
| <b>Equity</b>                                  | <b>6,346</b>  | <b>6,250</b>  | <b>5,532</b> | <b>Non Current Assets</b>             | <b>8,098</b>  | <b>8,117</b>  | <b>7,912</b> |
| Equity Share Capital                           | 336           | 518           | 518          | a) Property, Plant and Equipment      | 5,189         | 5,062         | 4,907        |
| Other Equity                                   | 6,010         | 5,732         | 5014         | b) Other Intangible assets            | -             | 1             | 1            |
|  |               |               |              | c) Capital Work In Progress           | 579           | 590           | 582          |
| <b>Non Current Liabilities</b>                 | <b>1,113</b>  | <b>337</b>    | <b>471</b>   | d) Investment in Subsidiary/Associate | 1,403         | 1,403         | 1,403        |
| a) Financial Liabilities                       |               |               |              | e) Financial Assets                   |               |               |              |
| (i) Borrowings                                 | 952           | 267           | 398          | (i) Investments                       | 1             | -             | -            |
| (ii) Trade Payable                             | 5             | 17            | 15           | (ii) Trade Receivable                 | 12            | 8             | 4            |
| (iii) Other Financial Liabilities              | 12            | 13            | 12           | (iii) Other financial assets          | 119           | 121           | 121          |
| b) Provisions                                  | 144           | 40            | 46           | f) Other Non - Current Assets         | 698           | 779           | 728          |
| c) Deferred Tax Liabilities (Net)              | -             | -             | -            | g) Deferred Tax Assets (Net)          | 97            | 153           | 166          |
| d) Other Non Current Liabilities               | -             | -             | -            | <b>Current Assets</b>                 | <b>2,832</b>  | <b>2,449</b>  | <b>2,069</b> |
|  |               |               |              | a) Inventories                        | 1,070         | 1,158         | 1,000        |
| <b>Current Liabilities</b>                     | <b>3,471</b>  | <b>3,979</b>  | <b>3,978</b> | b) Financial Assets                   |               |               |              |
| a) Financial Liabilities                       |               |               |              | (i) Trade Receivables                 | 1,446         | 1,034         | 839          |
| (i) Borrowings                                 | 534           | 692           | 33           | (ii) Cash and Cash Equivalents        | 40            | 42            | 8            |
| (ii) Trade Payables                            | 2,072         | 2,606         | 2,935        | (iii) Bank balances other than above  | 17            | 18            | 20           |
| (iii) Other Financial Liabilities              | 422           | 255           | 240          | (iv) Loans                            | 94            | 29            | 33           |
| b) Other Current liabilities                   | 421           | 401           | 744          | (v) Other financial assets            | 43            | 21            | 10           |
| c) Provisions                                  | 22            | 25            | 26           | c) Current Tax Assets (Net)           | 5             | 16            | 32           |
| d) Current Tax Liabilities (Net)               | -             | -             | -            | d) Other Current Assets               | 117           | 131           | 127          |
| <b>GRAND TOTAL - EQUITIES &amp; LIABILITES</b> | <b>10,930</b> | <b>10,566</b> | <b>9,981</b> | <b>GRAND TOTAL – ASSETS</b>           | <b>10,930</b> | <b>10,566</b> | <b>9,981</b> |



# Historical Consolidated Income Statement


| PARTICULARS (INR Mn)              | FY20          | FY21         | FY22         | H1-FY23      |
|-----------------------------------|---------------|--------------|--------------|--------------|
| Revenue from Operations           | 13,054        | 9,570        | 14,969       | 5,188        |
| Total Expenses                    | 11,193        | 8,744        | 13,756       | 5,344        |
| EBITDA                            | 1,861         | 826          | 1,213        | (156)        |
| <i>EBITDA Margins (%)</i>         | <b>14.26%</b> | <b>8.63%</b> | <b>8.10%</b> | <b>NA</b>    |
| Other Income                      | 53            | 22           | 20           | 3            |
| Depreciation                      | 444           | 461          | 502          | 245          |
| Finance Cost                      | 49            | 40           | 48           | 26           |
| <b>PBT</b>                        | <b>1,421</b>  | <b>347</b>   | <b>683</b>   | <b>(424)</b> |
| Tax                               | 264           | 129          | 154          | 102          |
| <i>Profit After Tax</i>           | <b>1,157</b>  | <b>218</b>   | <b>529</b>   | <b>(526)</b> |
| <i>PAT Margins (%)</i>            | <b>8.86%</b>  | <b>2.28%</b> | <b>3.53%</b> | <b>NA</b>    |
| Income from Associate             | 2,598         | 2,307        | 3,359        | 1,688        |
| Other Comprehensive Income        | (5)           | (1)          | (3)          | -            |
| <b>Total Comprehensive Income</b> | <b>3,750</b>  | <b>2,524</b> | <b>3,885</b> | <b>1,142</b> |
| Diluted EPS (INR per share)       | 72.34         | 48.69        | 74.94        | 22.03        |

# Consolidated Balance Sheet


| PARTICULARS (INR Mn)                           | FY21          | FY22          | H1-FY23       | PARTICULARS (INR Mn)                  | FY21          | FY22          | H1-FY23       |
|--|---------------|---------------|---------------|---------------------------------------|---------------|---------------|---------------|
| <b>Equity</b>                                  | <b>21,844</b> | <b>25,726</b> | <b>26,862</b> | <b>Non Current Assets</b>             | <b>21,580</b> | <b>24,949</b> | <b>26,412</b> |
| Equity Share Capital                           | 336           | 518           | 518           | a) Property, Plant and Equipment      | 5,591         | 5,430         | 5,264         |
| Other Equity                                   | 21,508        | 25,208        | 26,344        | b) Other Intangible assets            | 42            | 28            | 21            |
|  |               |               |               | c) Capital Work In Progress           | 584           | 629           | 630           |
| <b>Non Current Liabilities</b>                 | <b>1,125</b>  | <b>351</b>    | <b>485</b>    | d) Investment in Subsidiary/Associate | 14,447        | 17,806        | 19,473        |
| a) Financial Liabilities                       |               |               |               | e) Financial Assets                   |               |               |               |
| (i) Borrowings                                 | 952           | 267           | 398           | (i) Investments                       | 1             | -             | -             |
| (ii) Trade Payable                             | 5             | 17            | 15            | (ii) Trade Receivable                 | 12            | 8             | 4             |
| (iii) Other Financial Liabilities              | 12            | 13            | 12            | (iii) Other financial assets          | 131           | 134           | 135           |
| b) Provisions                                  | 156           | 54            | 60            | f) Other Non – Current Assets         | 700           | 781           | 739           |
| c) Deferred Tax Liabilities (Net)              | -             | -             | -             | g) Deferred Tax Assets (Net)          | 72            | 133           | 146           |
| d) Other Non Current Liabilities               | -             | -             | -             | <b>Current Assets</b>                 | <b>5,420</b>  | <b>5,793</b>  | <b>5,345</b>  |
|  |               |               |               | a) Inventories                        | 1,690         | 2,451         | 2,001         |
| <b>Current Liabilities</b>                     | <b>4,031</b>  | <b>4,665</b>  | <b>4,410</b>  | b) Financial Assets                   |               |               |               |
| a) Financial Liabilities                       |               |               |               | (i) Trade Receivables                 | 3,293         | 2,887         | 2,615         |
| (i) Borrowings                                 | 534           | 692           | 33            | (ii) Cash and Cash Equivalents        | 74            | 132           | 127           |
| (ii) Trade Payables                            | 2,563         | 3,248         | 3,277         | (iii) Bank balances other than above  | 30            | 54            | 360           |
| (iii) Other Financial Liabilities              | 432           | 263           | 249           | (iv) Loans                            | 92            | 30            | 23            |
| b) Other Current liabilities                   | 478           | 425           | 776           | (v) Other financial assets            | 44            | 21            | 10            |
| c) Provisions                                  | 22            | 26            | 27            | c) Current Tax Assets (Net)           | 5             | 15            | 32            |
| d) Current Tax Liabilities (Net)               | 2             | 11            | 48            | d) Other Current Assets               | 192           | 203           | 177           |
| <b>GRAND TOTAL - EQUITIES &amp; LIABILITES</b> | <b>27,000</b> | <b>30,742</b> | <b>31,757</b> | <b>GRAND TOTAL – ASSETS</b>           | <b>27,000</b> | <b>30,742</b> | <b>31,757</b> |

# Consolidated Financial Highlights


### Operational Revenue (INR Mn)




### EBITDA (INR Mn)\* & EBITDA Margins (%)\*




### PAT (INR Mn)\* & PAT Margins (%)\*




### RoE and RoCE (%)\*



### Net Debt to Equity (x)




### Net Worth (INR Mn)



\*Before share of profit of associate and OCI

# Capital Markets

## Stock Market Performance (as on 30<sup>th</sup> September, 2022)




### Price Data (As on 30<sup>th</sup> September, 2022)

INR

|                                  |           |
|----------------------------------|-----------|
| Face Value                       | 10.0      |
| Market Price                     | 503.1     |
| 52 Week H/L                      | 569/421   |
| Market Cap (Mn)                  | 26,077.79 |
| Equity Shares Outstanding (Mn)   | 51.8      |
| 1 Year Avg Trading Volume ('000) | 195.5     |

### Shareholding Pattern (As on 30<sup>th</sup> September, 2022)



# Disclaimer

## Kiri Industries Limited Disclaimer:

The information contained in this presentation is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care off in the presentation and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this presentation or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries were such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this presentation independent consultation / advise may be obtained and necessary due diligence, investigation etc. may be done at your end. You may also contact us directly for any questions or clarifications at our end. This presentation contain certain statements of future expectations and other forward-looking statements, including those relating to our general business plans and strategy, our future financial condition and growth prospects, and future developments in our industry and our competitive and regulatory environment. In addition to statements which are forward looking by reason of context, the words 'may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, potential or continue and similar expressions identify forward looking statements. Actual results, performances or events may differ materially from these forward-looking statements including the plans, objectives, expectations, estimates and intentions expressed in forward looking statements due to a number of factors, including without limitation future changes or developments in our business, our competitive environment, telecommunications technology and application, and political, economic, legal and social conditions in India. It is cautioned that the foregoing list is not exhaustive This presentation is not being used in connection with any invitation of an offer or an offer of securities and should not be used as a basis for any investment decision

## Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

**For further details, please feel free to contact our Investor Relations Representatives:**



Mr. Anuj Sonpal  
Valorem Advisors  
Tel: +91-22-4903-9500  
Email: [kiri@valoremadvisors.com](mailto:kiri@valoremadvisors.com)



**THANK YOU**